Lim Annette M, Cavanagh Karda, Hicks Rodney J, McLean Luke, Goh Michelle S, Webb Angela, Rischin Danny
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, VIC, Australia.
Front Oncol. 2021 Apr 15;11:656611. doi: 10.3389/fonc.2021.656611. eCollection 2021.
Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon "delayed response after confirmed progression (DR)". We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use.
非黑色素瘤皮肤癌是全球诊断出的最常见癌症之一，在澳大利亚和新西兰发病率最高。局部晚期和转移性皮肤鳞状细胞癌的全身治疗因PD -1阻断的免疫检查点抑制而发生了变革。我们强调了该疾病管理中独特的治疗问题，包括扩展假性进展的传统概念，并描述了在免疫特异性反应标准确认疾病进展（无论有无临床恶化）后出现的延迟反应。我们将这种现象称为“确认进展后的延迟反应（DR）”。我们还讨论了第二原发性肿瘤的常见发生、疾病反应的异质性以及免疫治疗应用不断扩大的临床界限。
